# Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Canonical URL: https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted-cd19-cd70-allogeneic-car-t-for-autoimmune-diseases
Ticker: ALLO
Company: Allogene Therapeutics
Source: Allogene Therapeutics
Published: 2026-04-15 12:30 EST
Original Source URL: https://ir.allogene.com
## Summary

Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical Models Dual CD19/CD70 CAR T Cells Rapidly Eliminated B and T Cells in Systemic Lupus

## Article Body
Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical Models Dual CD19/CD70 CAR T Cells Rapidly Eliminated B and T Cells in Systemic Lupus
## Recent Company News
- 2026-05-28 21:02 EST — [Allogene Therapeutics Announces Planned CEO Succession](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession) — Source: Allogene Therapeutics
- 2026-05-26 12:30 EST — [Allogene Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Allogene Therapeutics
- 2026-05-13 20:02 EST — [Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-05-06 12:30 EST — [Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-financial-results-and-provide-business-update) — Source: Allogene Therapeutics
- 2026-04-21 12:30 EST — [Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia) — Source: Allogene Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)